Rona Therapeutics｜Innovative siRNA Medicines & RNA Therapeutics Platform ©2025 Rona Therapeutics Home About Us Company Management Team Investors Partners Events Platform & Pipeline Platform Pipeline News Center News Join Us R&D Center Corporate Culture Recruitment Contact Us English English 中文版 More LEARN MORE UNLOCKING siRNA'S POWER FOR NEXT-GEN THERAPIES SCROLL Rona Therapeutics' metabolic assets have demonstrated a differentiated profile to address unmet medical needs in cardiovascular diseases, obesity and MASH PLATFORM GAIA Liver delivery platform Long dosing intervals to improve patient compliance Convenient subcutaneous injection Novel GalNAc and chemical modifications to improve potency and safety APOLLO Extraheptic delivery platform Small molecule conjugation for efficient receptor mediated uptake throughout the CNS Intrathecal local delivery to minimize side effects associated with systemic exposure Q6M or longer dosing schedule with proof-of-concept in non-human primates Bi-Valent/Multi-Valent Plug-and-Play Scalable Platform Ideal for complex diseases caused by multiple factors, such as cardiovascular diseases and obesity Potential to treat two or more diseases by impacting two targets Synergistic efficacy without added side effects Streamline development and better marketing potential than fixed dose combination PIPELINE GAlA Platform RN0361 Hypertriglyceridemia ApoC3 Preclinical IND-Enabling Ph1 Ph2 Ph3 RN3161 Obesity INHBE Preclinical IND-Enabling Ph1 Ph2 Ph3 RN5681 ASCVD PCSK9-Lp(a) Preclinical IND-Enabling Ph1 Ph2 Ph3 More Products NEWS More 10/ 11 Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions 15/ 09 Rona Therapeutics Announces IND Filing of RN3161, a Highly Potent and Durable INHBE siRNA for Obesity 21/ 04 Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension CONTACT US China Email: BD@******************** / HR@******************** Address: Tower 3, JNB Life Science Park, No.795, Kangwei Road, Pudong New Area, Shanghai, China Australia Email: BD@******************** Address: Se 2 202-220 FERNTREE GULLY RD CLAYTON VIC 3168 United States Email: BD@******************** Address: State of Delaware About Us Company Management Team Partners News Center Join US R&D Center Corporate Culture Recruitment Contact Us Platform and Pipeline Platform Pipeline Subscribe To Our Newsletter Please read on, stay posted, subscribe and we welcome you to tell us what you think Privacy Policy | 沪ICP备2021031795号 Web Design by ******* Copyright ©2025 Rona Therapeutics All rights reserved Web Design by ******* Jinyu Huang, Ph.D. Chief Executive Officer, Founder Stella Shi is founder, Chief Executive Officer and chairs the board of Rona Therapeutics since company inception in 2021 bringing ~15 years of biopharmaceutical industry and venture capital experience. Prior to founding Rona Therapeutics, Stella was managing director in Lilly Asia Ventures (LAV) from 2015 with proven track records with various venture creation ... 0% AUPO has made its way to the top manufacturer of thermal cutoffs in the world.
